Fed. Circ. Amgen Biosimilar Ruling Raises IP Damages Risk
Law360 (February 26, 2020, 4:53 PM EST) -- The U.S. Court of Appeals for the Federal Circuit recently affirmed a $70 million jury award for infringement of a manufacturing process patent for a biosimilar product without any infringing sales. The damages award in this case was particularly notable because the patentee did not practice the claimed technology.
This decision highlights a real risk facing drug companies developing a biosimilar product: The reference sponsor's patent portfolio may include dozens of patents that surround every step and variable in the manufacturing process, including alternatives that the reference sponsor itself does not use. This decision also highlights the benefits to innovator companies...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!